{"acute kidney injury": 5.39, "anaemia": 5.32, "atypical haemolytic uraemic syndrome": 152.06, "cardiac failure": 9.49, "cardiotoxicity": 14.14, "covid-19 pneumonia": 6.96, "cytokine release syndrome": 3.86, "cytopenia": 16.33, "disease progression": 3.47, "ejection fraction decreased": 7.94, "febrile neutropenia": 6.4, "haemolytic anaemia": 7.88, "infection": 3.01, "infusion related reaction": 7.69, "intentional product use issue": 11.07, "leukopenia": 3.15, "lymphopenia": 7.61, "microangiopathic haemolytic anaemia": 141.67, "mucosal inflammation": 4.57, "multiple organ dysfunction syndrome": 3.73, "myelosuppression": 3.78, "neuropathy peripheral": 4.64, "neutropenia": 4.68, "neutrophil count decreased": 2.38, "off label use": 6.5, "pancytopenia": 5.81, "plasma cell myeloma": 184.38, "plasma cell myeloma recurrent": 291.94, "plasma cell myeloma refractory": 518.17, "plasmacytoma": 160.33, "platelet count decreased": 3.69, "pleural effusion": 3.93, "pneumonia": 3.85, "progressive multifocal leukoencephalopathy": 25.56, "pulmonary arterial hypertension": 7.48, "pulmonary hypertension": 6.66, "pulmonary oedema": 2.69, "renal failure": 3.15, "respiratory failure": 3.09, "sepsis": 4.65, "septic shock": 2.6, "therapeutic product effect incomplete": 4.56, "therapy non-responder": 19.32, "therapy partial responder": 83.15, "thrombocytopenia": 8.17, "thrombotic microangiopathy": 116.92, "tumour lysis syndrome": 44.18}